Johnson & Johnson reported mixed results for the first quarter of 2022, beating earnings estimates with $2.67 per share but missing revenue expectations at $23.43 billion. The company is facing increased scrutiny over counterfeit HIV medications, prompting it to file a lawsuit against drug distributors and a pharmacy while seeking to block further counterfeit sales and claim at least $25 million in damages from each defendant. Despite these challenges, J&J has tested all-time highs and continues to maintain a strong dividend growth record with 60 consecutive years of increases.
“Johnson & Johnson · has tested · all-time highs”
“Johnson & Johnson · is trading at · 17 forward P/E”
“Johnson & Johnson · reported earnings · 2.67 per share · beat analysts' estimates of 2.56 per share”
“Johnson & Johnson · reported revenue · 23.43 billion · missed analysts' expectations by 1.6%”
“Johnson & Johnson · dividend growth duration · 59 years”
“Johnson & Johnson · reported · mixed results · beating on earnings but missing revenue estimates”
“Johnson & Johnson · reported · mixed first-quarter results”
“Johnson & Johnson · has raised · its dividend · for 60 consecutive years”
“Johnson & Johnson · reported revenues · of · $23.4 billion”
“Johnson & Johnson · maintains a payout ratio · of · 57%”
“Johnson & Johnson · has a compounded annual revenue growth rate · of · 5.6%”
“Johnson & Johnson · is expected to generate revenues · in the range of · $94.8 billion to $95.8 billion”
